image
MDxHealth SA MDXH
Healthcare - Medical - Diagnostics & Research - NASDAQ - BE
Watchlist
$ 1.6
0 %
$ 79.2 M
Market Cap
-1.38
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one MDXH stock under the worst case scenario is HIDDEN Compared to the current market price of 1.6 USD, MDxHealth SA is HIDDEN

MDXH Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one MDXH stock under the base case scenario is HIDDEN Compared to the current market price of 1.6 USD, MDxHealth SA is HIDDEN

MDXH Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one MDXH stock under the best case scenario is HIDDEN Compared to the current market price of 1.6 USD, MDxHealth SA is HIDDEN

MDXH Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart MDXH

image
1M 7.0%
6M -27%
1Y -96%
3Y -431.0%
5Y --%
All
$2.6$2.6$2.4$2.4$2.2$2.2$2.0$2.0$1.8$1.8$1.6$1.6$1.4$1.4Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
90 M REVENUE
28.29%
Growth Rates
1Year 28.29%
3Years 59.39%
5Years 50.19%
7Years 12.09%
10Years 22.87%
-24.7 M OPERATING INCOME
9.53%
Growth Rates
1Year 9.53%
3Years 2.70%
5Years 10.55%
7Years -10.52%
10Years -4.89%
-38.1 M NET INCOME
11.67%
Growth Rates
1Year 11.67%
3Years -12.35%
5Years 2.48%
7Years -17.55%
10Years -9.51%
-18.5 M OPERATING CASH FLOW
13.80%
Growth Rates
1Year 13.80%
3Years 6.33%
5Years 3.63%
7Years -8.47%
10Years -0.01%
-1.64 M INVESTING CASH FLOW
58.38%
Growth Rates
1Year 58.38%
3Years -22.73%
5Years -86.25%
7Years 17.05%
10Years -2.68%
44.6 M FINANCING CASH FLOW
38.16%
Growth Rates
1Year 38.16%
3Years -12.47%
5Years 19.94%
7Years 86.28%
10Years 11.76%
24.7 M REVENUE
6.10%
Growth Rates
1Year 28.29%
3Years 59.39%
5Years 50.19%
7Years 12.09%
10Years 22.87%
-4.61 M OPERATING INCOME
24.36%
Growth Rates
1Year 9.53%
3Years 2.70%
5Years 10.55%
7Years -10.52%
10Years -4.89%
-4.61 M NET INCOME
24.36%
Growth Rates
1Year 11.67%
3Years -12.35%
5Years 2.48%
7Years -17.55%
10Years -9.51%
-3.12 M OPERATING CASH FLOW
44.51%
Growth Rates
1Year 13.80%
3Years 6.33%
5Years 3.63%
7Years -8.47%
10Years -0.01%
-229 K INVESTING CASH FLOW
-1661.54%
Growth Rates
1Year 58.38%
3Years -22.73%
5Years -86.25%
7Years 17.05%
10Years -2.68%
884 K FINANCING CASH FLOW
-97.37%
Growth Rates
1Year 38.16%
3Years -12.47%
5Years 19.94%
7Years 86.28%
10Years 11.76%
Balance Sheet MDxHealth SA
image
Current Assets 66.9 M
Cash & Short-Term Investments 46.8 M
Receivables 14.5 M
Other Current Assets 5.56 M
Non-Current Assets 90.4 M
Long-Term Investments 936 K
PP&E 13 M
Other Non-Current Assets 76.5 M
29.75 %9.24 %3.54 %8.25 %48.64 %Total Assets$157.3m
Current Liabilities 42.7 M
Accounts Payable 8 M
Short-Term Debt 1.68 M
Other Current Liabilities 33 M
Non-Current Liabilities 99.8 M
Long-Term Debt 58.4 M
Other Non-Current Liabilities 41.4 M
5.62 %23.14 %40.97 %29.09 %Total Liabilities$142.5m
EFFICIENCY
Earnings Waterfall MDxHealth SA
image
Revenue 90 M
Cost Of Revenue 34.9 M
Gross Profit 55.1 M
Operating Expenses 79.9 M
Operating Income -24.7 M
Other Expenses 13.3 M
Net Income -38.1 M
100m100m80m80m60m60m40m40m20m20m00(20m)(20m)(40m)(40m)90m(35m)55m(80m)(25m)(13m)(38m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
61.23% GROSS MARGIN
61.23%
Averages
1Year 61.23%
3Years 58.56%
5Years 53.05%
7Years 46.13%
10Years 52.43%
-27.45% OPERATING MARGIN
-27.45%
Averages
1Year -27.45%
3Years -56.22%
5Years -87.40%
7Years -130.94%
10Years -107.22%
-42.28% NET MARGIN
-42.28%
Averages
1Year -42.28%
3Years -79.71%
5Years -108.26%
7Years -145.93%
10Years -117.88%
-256.51% ROE
-256.51%
Averages
1Year -256.51%
3Years -464.42%
5Years -394.42%
7Years -321.84%
10Years -233.88%
-24.20% ROA
-24.20%
Averages
1Year -24.20%
3Years -33.23%
5Years -47.01%
7Years -55.81%
10Years -45.62%
-21.46% ROIC
-21.46%
Averages
1Year -21.46%
3Years -29.33%
5Years -51.88%
7Years -64.87%
10Years -53.41%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis MDxHealth SA
image
00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)(30m)(30m)(35m)(35m)(40m)(40m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -38.1 M
Depreciation & Amortization 8.04 M
Capital Expenditures -1.19 M
Stock-Based Compensation 1.72 M
Change in Working Capital -3.86 M
Others 14.1 M
Free Cash Flow -19.7 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets MDxHealth SA
image
MDXH has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 5
6. Ownership
Insider Ownership MDxHealth SA
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Down -15.22% in 4 Weeks, Here's Why You Should You Buy the Dip in MDxHealth SA (MDXH) MDxHealth SA (MDXH) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. zacks.com - 1 month ago
MDxHealth SA (MDXH) Q4 2024 Earnings Call Transcript MDxHealth SA (NASDAQ:MDXH ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants John Fraunces - LifeSci Advisors, IR Michael McGarrity - Chief Executive Officer Ron Kalfus - Chief Financial Officer Conference Call Participants Thomas Flaten - Lake Street Andrew Brackmann - William Blair Thomas Vranken - KBC Securities Jason Bednar - Piper Sandler Vidyun Bais - BTIG Dan Brennan - TD Cowen Operator Good day. And welcome to the MDxHealth Fourth Quarter and Full Year 2024 Earnings Call. seekingalpha.com - 2 months ago
MDxHealth SA (MDXH) Reports Q4 Loss, Tops Revenue Estimates MDxHealth SA (MDXH) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.39 per share a year ago. zacks.com - 2 months ago
Mdxhealth Announces Fourth Quarter and Full-Year 2024 Financial Results Fourth quarter revenue growth of 28% to $24.7 million 2024 revenue growth of 28% to $90.0 million 68% improvement in adjusted EBITDA in fourth quarter Conference call with Q&A today at 4:30 PM EST / 22:30 CET globenewswire.com - 2 months ago
MDxHealth Reports Preliminary Fourth Quarter and Full Year 2024 Revenues and Issues 2025 Revenue Guidance MDxHealth Reports Preliminary Fourth Quarter and Full Year 2024 Revenues and Issues 2025 Revenue Guidance IRVINE, CA – January 13, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today reported preliminary fourth quarter and full year 2024 revenues and issued 2025 revenue guidance. The Company expects to report fourth quarter and full year 2024 revenues of approximately $24.7 and $90.0 million, respectively, representing year-over-year growth of 28% for both periods. globenewswire.com - 3 months ago
MDxHealth: Strong Buy On Its Cutting-Edge Urology Diagnostics MDxHealth SA offers a comprehensive portfolio of precision diagnostics targeting all stages of prostate cancer and advanced UTI detection, addressing a $4.9 billion TAM. The company's flagship products, ConfirmMDx (post-biopsy detection), SelectMDx (pre-biopsy screening), and GPS (treatment planning), are driving clinical adoption. MDxHealth achieved 21% YoY revenue growth in Q3 2024, with management forecasting positive EBITDA by 2025 through disciplined cash management and market penetration. seekingalpha.com - 4 months ago
MDxHealth to Participate in Piper Sandler Healthcare Conference MDxHealth to Participate in Piper Sandler Healthcare Conference IRVINE, CA – November 25, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced that Michael K. McGarrity, Chief Executive Officer, will participate in the Piper Sandler 36th Annual Healthcare Conference, which will take place between Dec 3-5, 2024, in New York City. globenewswire.com - 5 months ago
MDxHealth SA (MDXH) Q3 2024 Earnings Call Transcript MDxHealth SA (NASDAQ:MDXH ) Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ET Company Participants Michael K. McGarrity - Chief Executive Officer and Director Ron Kalfus - Chief Financial Officer Conference Call Participants Vidyun Bais - BTIG Thomas Flaten - Lake Street Capital Markets Jason Bednar - Piper Sandler Operator Good day, and welcome to the MDxHealth Third Quarter 2024 Earnings Call. seekingalpha.com - 5 months ago
MDxHealth Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2024 Tissue-based test volumes increase by 36%, liquid-based test volumes by 24% Company raises 2024 revenue guidance to $87-89 million, representing 25% growth Pro-forma cash of $53.5 million Conference call and webcast today at 4:30pm ET IRVINE, CA – November 6, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced its financial results for the third quarter and nine-month period ended September 30, 2024. Michael K. globenewswire.com - 5 months ago
MDxHealth Announces Pricing of Offering of Ordinary Shares MDxHealth Announces Pricing of Offering of Ordinary Shares IRVINE, CA, and HERSTAL, BELGIUM – September 25, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (“mdxhealth” or the “Company“), a commercial-stage precision diagnostics company, today announced that it has priced a registered public offering of 20,000,000 ordinary shares of the Company without nominal value (“Ordinary Shares”) in a registered public offering (the “Offering”) at a price to the public of $2.00 per Ordinary Share for total gross proceeds of $40.0 million before deducting commissions and estimated offering expenses. A strategic partner is purchasing 1,500,000 Ordinary Shares in this Offering directly from the Company rather than through the underwriters. globenewswire.com - 7 months ago
MDxHealth Announces Launch of Offering of Ordinary Shares MDxHealth Announces Launch of Offering of Ordinary Shares IRVINE, CA, and HERSTAL, BELGIUM –September 25, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (“mdxhealth” or the “Company”), a commercial-stage precision diagnostics company, announced the launch of a proposed offering of $40.0 million of ordinary shares of the Company without nominal value ("Ordinary Shares") in a registered public offering (the “Offering”). The Company also expects to grant the underwriters a 30-day option to purchase up to 15% of the Ordinary Shares being offered, excluding any Ordinary Shares purchased directly from the Company in the Offering pursuant to any separate Securities Purchase Agreement. globenewswire.com - 7 months ago
MDxHealth SA (MDXH) Q2 2024 Earnings Call Transcript MDxHealth SA (NASDAQ:MDXH ) Q2 2024 Earnings Conference Call August 21, 2024 4:30 PM ET Company Participants Michael McGarrity - CEO Ron Kalfus - CFO Conference Call Participants Andrew Brackmann - William Blair Vidyun Bais - BTIG Thomas Vranken - KBC Securities Jason Bednar - Piper Sandler Operator Greetings, and welcome to the MDxHealth Second Quarter 2024 Earnings Call. [Operator Instructions] As a reminder, this call is being recorded. seekingalpha.com - 8 months ago
8. Profile Summary

MDxHealth SA MDXH

image
COUNTRY BE
INDUSTRY Medical - Diagnostics & Research
MARKET CAP $ 79.2 M
Dividend Yield 0.00%
Description MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
Contact CAP Business Center, Herstal, 4040 https://mdxhealth.com
IPO Date Nov. 4, 2021
Employees 312
Officers Mr. Joseph Sollee J.D., LLM Executive Vice President of Corporate Development & General Counsel Mr. John A. Bellano Chief Commercial Officer Mr. Ron Kalfus CPA Chief Financial Officer Mr. Michael K. McGarrity Chief Executive Officer & Executive Director Ms. Miriam Reyes Executive Vice President of Operations